December 14, 2020
InnoSkel Launches with €20 Million Series A Financing
GlobeNewswire
InnoSkel Launches with €20 Million Series A Financing
Proceeds to support development and advancement of innovative gene therapies for patients with rare skeletal diseases
Founded and led by industry veteran and renowned scientist, Elvire Gouze, PhD
Series A Financing co-led by Jeito Capital and Vida Ventures, with support from Turenne Group and Région Sud Investissement
Nice, France, 14 December 2020 – InnoSkel, a newly launched platform biotechnology company pioneering gene therapies for rare skeletal diseases, today announced that it has raised €20 million in a Series A financing round. The fundraise was co-led by Jeito Capital and Vida Ventures, with additional support from Turenne Group and Région Sud Investissement. Proceeds from the financing will be used to advance the company’s lead program to clinical stage operations. InnoSkel was founded by Elvire Gouze, PhD, a scien
Share:
Jeito Capital leads €20 Million Investment in InnoSkel, a New Gene Therapy Company and leader in rare skeletal disorders
Jeito s third international investment in H2 2020, with deep and rapidly accelerating pipeline
Therachon s Founder, Elvire Gouze, launches latest new gene therapy company in her field of excellence
€20 million Series A financing, sees Jeito co-investing again with Vida Ventures
Paris, France, 14 December 2020 – Jeito Capital ( Jeito ), a rapidly emerging independent investor dedicated to biotech and biopharma, today announces that it has led a €20 million Series A financing in InnoSkel, a newly launched pioneering platform biotechnology company developing therapies for rare and life-threatening skeletal diseases. Jeito co-led the financing in a high-quality syndicate with Vida Ventures and with additional support from The Turenne Group. InnoSkel becomes Jeito s third investment in the past four months, following SparingVision and Neogene, and Je